

23  
CLAIMS

1. A method for the prophylaxis or treatment of a respiratory disorder in a mammalian host by inhalation of a metered dry powder combined dose of finely divided dry medication powders, **characterized** by the steps of
- selecting at least one dry powder medicament from a first group of bronchodilating medicaments and at least one dry powder medicament from a second group of anti-inflammatory medicaments;
- 10       preparing a metered dry powder medicinal combined dose comprising separately metered deposits of medicinally suitable quantities of each of the selected medicaments, where the sum of the metered deposits constitutes the metered quantity of powder of a medicinal combined dose;
- introducing the medicinal combined dose into an inhaler device for
- 15   delivery of the medicinal combined dose during the course of a single inhalation by a user, such that the delivered medicinal combined dose is composed of a high proportion of mixed de-aggregated fine particles of the selected medicaments respectively, whereby an intended therapeutic or treating effect to the user is achieved.
- 20
2. The method according to claim 1, **characterized by** the further step of
- using formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof from the first group of
- 25   bronchodilating medicaments as a first medicament and budesonide or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof from the second group of anti-inflammatory medicaments as a second medicament.
- 30
3. The method according to claim 1, **characterized by** the further step of

using formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof from the first group of bronchodilating medicaments as a first medicament and fluticasone or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof from the second group of anti-inflammatory medicaments as a second medicament.

4. The method according to claim 1, **characterized by** the further step of

10 using formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof from the first group of bronchodilating medicaments as a first medicament and mometasone or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof from the second group of antiinflammatory medicaments as  
15 a second medicament.

5. The method according to claim 1, **characterized by** the further step of

20 using formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof from the first group of bronchodilating medicaments as a first medicament and ciclesonide or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof from the second group of antiinflammatory medicaments as  
25 a second medicament.

6. The method according to claim 1, **characterized by** the further step of

30 using one or more of the substances Albuterol (also known as Salbutamol), Bambuterol, Bitolterol, Broxaterol, Carbuterol, Clenbuterol, Etanterol, Fenoterol, Formoterol, Hexoprenaline, Imoxiterol, Isoetharine, Metaproterenol, Naminterol, Picumeterol, Pirbuterol, Procaterol, Rimiterol, Reproterol, Salmeterol, Terbutaline, Tiotropium and Tulobuterol or

pharmaceutically acceptable salts, enantiomers, racemates, hydrates, solvates, or mixtures thereof belonging to the first group of bronchodilating medicaments as a first medicament and one or more of the substances Budesonide, Beclomethasone, Ciclesonide, Dexametasone, Flunisolide, 5 Fluticasone, Ipratropium, Mometasone and Triamcinolone or pharmaceutically acceptable salts, enantiomers, racemates, hydrates, solvates, or mixtures thereof belonging to the second group of anti-inflammatory medicaments as a second medicament.

10 7. The method according to claim 1, **characterized by** the further step of

preparing the dry powder medicinal combined dose to a total mass in a range from 10 µg to 50 mg.

15 8. The method according to claim 1, **characterized by** the further step of

separating the deposits of the included medicaments from each other onto a dose bed, such that the medicaments cannot detrimentally mix with each other after forming of the combined dose.

20

9. The method according to claim 1, **characterized by** the further step of

selecting a continuous dry powder inhaler (DPI) designed for a prolonged delivery of the medicinal combined dose to a user inhaling once 25 through the DPI.

10. A pharmaceutical dry powder combined dose, adapted for inhalation, for the prophylaxis or treatment of a respiratory disorder in a mammalian host **characterized** in that

30 at least one medicament from a first group of bronchodilating medicaments and at least one medicament from a second group of anti-inflammatory medicaments are selected;

the pharmaceutical dry powder combined dose is prepared comprising separate, metered deposits of a medicinally suitable quantity of the selected medicaments from the first and second groups of medicaments respectively, where the sum of the deposits constitute the metered quantity of powder in the pharmaceutical, combined dose;

the pharmaceutical dry powder combined dose is introduced into an inhaler device for a user initiated delivery of the pharmaceutical dry powder combined dose, whereby the first and second medicaments of the combined dose are delivered to the host user during the course of a single inhalation;

the combined therapeutical effect of the inhaled medicinal dosage comprising two selected medicaments is medically, psychologically or socially beneficial to the host user in need of such combined treatment.

11. The pharmaceutical dry powder combined dose according to claim 10, **characterized in** that

formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected from the first group of bronchodilating medicaments as a first medicament and budesonide or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected from the second group of anti-inflammatory medicaments as a second medicament.

12. The pharmaceutical dry powder combined dose according to claim 10, **characterized in** that

formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected from the first group of bronchodilating medicaments as a first medicament and fluticasone or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected from the second group of anti-inflammatory medicaments as a second medicament.

13. The pharmaceutical dry powder combined dose according to claim 10, **characterized in that**

formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected from the first  
5 group of bronchodilating medicaments as a first medicament and mometasone or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected from the second group of anti-inflammatory medicaments as a second medicament.

10 14. The pharmaceutical dry powder combined dose according to claim 10, **characterized in that**

formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected from the first group of bronchodilating medicaments as a first medicament and ciclesonide  
15 or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected from the second group of anti-inflammatory medicaments as a second medicament.

15. The pharmaceutical dry powder combined dose according to  
20 claim 10, **characterized in that**

one or more of the substances Albuterol (also known as Salbutamol), Bambuterol, Bitolterol, Broxaterol, Carbuterol, Clenbuterol, Etanterol, Fenoterol, Formoterol, Hexoprenaline, Imoxiterol, Isoetharine, Metaproterenol, Naminterol, Picumeterol, Pirbuterol, Procaterol, Rimiterol,  
25 Reproterol, Salmeterol, Terbutaline, Tiotropium and Tulobuterol or pharmaceutically acceptable salts, enantiomers, racemates hydrates, solvates, or mixtures thereof belonging to the first group of bronchodilating medicaments may be used as a first medicament and one or more of the substances Budesonide, Beclomethasone, Ciclesonide, Dexametasone,  
30 Flunisolide, Fluticasone, Ipratropium, Mometasone and Triamcinolone or pharmaceutically acceptable salts, enantiomers, racemates hydrates,

solvates, or mixtures thereof belonging to the second group of antiinflammatory medicaments may be used as a second medicament.

16. The pharmaceutical dry powder combined dose according to  
5 claim 10, **characterized in** that  
the combined dose is prepared to a total mass in a range from 10  
µg to 50 mg.

17. The pharmaceutical dry powder combined dose according to  
10 claim 10, **characterized in** that  
the deposits of the included medicaments are suitably separated  
from each other onto a dose bed, such that the medicaments cannot  
detrimentally mix with each other after forming of the combined dose.